LifeMD, Inc. (NASDAQ:LFMD) Receives Average Rating of “Moderate Buy” from Analysts

Shares of LifeMD, Inc. (NASDAQ:LFMD) have been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $9.25.

Several brokerages have recently weighed in on LFMD. Loop Capital set a $8.00 price objective on shares of LifeMD in a research report on Monday, November 24th. BTIG Research decreased their price objective on shares of LifeMD from $18.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. B. Riley cut their target price on LifeMD from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Zacks Research raised LifeMD from a “strong sell” rating to a “hold” rating in a research report on Friday, December 19th. Finally, Lake Street Capital dropped their price target on LifeMD from $14.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th.

Insider Activity at LifeMD

In related news, CMO Jessica Friedeman sold 15,000 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $3.61, for a total value of $54,150.00. Following the completion of the sale, the chief marketing officer owned 205,000 shares in the company, valued at $740,050. This represents a 6.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 18.40% of the stock is owned by insiders.

Institutional Investors Weigh In On LifeMD

Institutional investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC raised its stake in shares of LifeMD by 148.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,656 shares of the company’s stock worth $50,000 after buying an additional 2,185 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in LifeMD by 110.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after acquiring an additional 2,452 shares during the period. Caitong International Asset Management Co. Ltd grew its holdings in LifeMD by 1,004.9% during the second quarter. Caitong International Asset Management Co. Ltd now owns 5,171 shares of the company’s stock worth $70,000 after acquiring an additional 4,703 shares during the period. Quarry LP purchased a new position in LifeMD in the third quarter worth $52,000. Finally, King Wealth Management Group acquired a new stake in LifeMD in the third quarter valued at $68,000. Hedge funds and other institutional investors own 35.52% of the company’s stock.

LifeMD Price Performance

NASDAQ:LFMD opened at $3.24 on Monday. The firm has a market capitalization of $155.96 million, a PE ratio of -19.06 and a beta of 1.45. The business’s fifty day moving average price is $3.63 and its 200 day moving average price is $5.73. LifeMD has a 12 month low of $3.18 and a 12 month high of $15.84.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings data on Monday, November 17th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The firm had revenue of $60.17 million during the quarter, compared to analyst estimates of $62.07 million. During the same quarter in the prior year, the firm posted $0.09 EPS. As a group, equities analysts anticipate that LifeMD will post -0.56 EPS for the current year.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.